Outcome of Board Meeting

Piramal Pharma Limited 29th July, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Outcome of Board Meeting of Piramal Pharma Limited (‘Company’) held on 29th July, 2026 Dear Sir / Madam, Kindly refer to our letter dated 20th July, 2026 on the subject. Pursuant to the provisions of Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), the Board of Directors of the Company at its meeting held today, i.e. 29th July, 2026, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026. In this regard, please find enclosed the following: a. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026; b. Limited Review Reports by the Statutory Auditors. Further, we are arranging to publish the above-mentioned financial results in newspapers as per Regulation 47 of the SEBI Listing Regulations. The above information is also available on the website of the Company at www.piramalpharma.com. The meeting of the Board of Directors commenced at 5:30 pm and concluded at 8:30 pm. You are requested to take the above information on record. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl.: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com Piramal Pharma Limited PIRAMAL PHARMA LIMITED Ananta Building, Piramal Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400 070 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2026 (Rs. in Crores) Three months ended Three months ended Three months ended For the year ended Particulars June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 (Unaudited) CR efer note 5 l (Unaudited) (Audited) Revenue from operations 1,124.95 1,489.06 969.88 4,782.01 Other income (Net) 114.63 183.69 180.92 662.73 Total Income 1,23g_58 1,672.75 1,150.80 5,444.74 Expenses Cost of materials consumed 649.70 234.93 409.76 1,342.70 Purchases of stock-in-trade 234.64 194.03 192.27 866.18 Changes in inventories of finished goods, work-in-progress and stock-in-trade (390.29) 225.25 (175.87) (138.98) Employee benefits expense 216.34 166.55 201.95 744.82 Finance costs 16.36 19.50 23.23 79.95 Depreciation & amortisation expense and impairment charge 65.73 70.12 59.44 255.50 Other expenses (Net) 297.62 364.95 297.44 1,325.29 Total Expenses 1,090.10 1,275.33 1,008.22 4,475.46 Profit before exceotional items and tax 149.48 397.42 142.58 969.28 Exceotional items /Refer Note 31 /65.571 /92.51 Profit before tax 149.48 331.85 142.58 876.77 Tax Expense Current tax-(induding prior year taxes) 24.93 43.11 19.63 114.68 Deferred tax (Net) 11.07 27.11 9.81 62.08 Total tax exoenses 36.00 70.22 29.44 176.76 Net Profit after tax 113.48 261.63 113.14 700.01 Other Comprehensive Income/ (Loss) (OCI), net of tax expense A. Items that will not be reclassified to profit or loss Remeasurement of post employment benefit plans (9.76) (10.19) (4.87) (12.50) Income tax impact on above 2.46 2.56 1.23 3.15 B. Items that wlll be subsequently reclassified to profit or loss Deferred gains/(loss) on cash flow hedge 3.07 (3.35) 1.24 (35.25) Income tax impact on above (0.77) 0.84 (0.31) 8.87 Total Other Comprehensive Income/ (Loss), net of tax (5.00) (10.14) (2.71) (35.73) expense Total Comprehensive Income for the period 108.48 251.49 110.43 664.28 Paid-up Equity Share Capital (Face Value of Rs. 10/-each) 1,327.35 1,327.16 1,324.82 1,327.16 Other Equity 6,813.97 Earnings Per Equity Share (EPS) (Face Value of Rs. 10/-each) (restated, not annualised for the quarters) a) Basic EPS for the period/year (Rs.) 0.85 1.97 0.85 5.28 b) Diluted EPS for the period/year (Rs.) 0.85 1.96 0.85 5.25 "D"°'AI?'~,l? ~ ... < See accompanying notes to the unaudited standalone financial results ~ ~ d, ..., ~~·~~ Piramal Pharma Limited ,,'.¥ * o"> CTN~L 242.9 . ifH2020PLC33859-2 Office: Anan!a Bmldmg, Pir.amal Corp,mil:e Park; Ow. Fm, Briga.de·, Kmsa,,i J~io:i, LB'8 Y,,,f:u.g, K"'~ {\Wrt), Mumh:ii-400070, 11.fam.rashlr.i; In,li~ Tel No, -f'.91 2.HS02 3000 / 4000; Email.Id: sharehol<lers. .p p~,"1/lpiranul..com u.-wu.Lpinm1,p}1¥Il'lia oom Piramal Pharma Limited Notes: 1 The unaudited standalone financial results of the Company for the three months ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on July 29, 2026. The Statutory auditors of the Company have carried out a limited review of these results. 2 The unaudited standalone financial results of the Company for the three months ended June 30, 2026 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. 3 There were no exceptional items during the quarter ended 30 June 2026. Exceptional items for the quarter and year ended 31 March 2026 aggregating Rs.92.51 crore comprised (i) impairment of an intangible asset under development of Rs.65.57 crore and (ii) incremental employee benefit cost of Rs.26.94 crore arising from the Company's assessment of the impact of the Labour Codes. 4 The Company operates in only one segment and hence segment disclosure is not applicable. 5 The figures for the last quarter of the previous financial year are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of third quarter of the previous financial year which were subjected to limited review by statutory auditors. For PIRAMAL PHARMA LIMITED July 29, 2026, Mumbai Nandini Piramal Chairperson Piramal Pharma. Limited CTN· I.24297MH2(12J)PLC33S592 ~"'ie,,ed. Oflke: .4nanta Building, Pir.amal Corporate Pairk:;: Qw. Fire Briga;de,Kamani J~ io:,, LBS I\fa1g, Kur~ (\Vert}, I\1mnba.i-400070, Mammbtra; India Tel No. -f'.9>1 2B S.Ol lOOO I 4000; Email.Id.: sbarehold=.pp ,~iramal= m .pin1nal,Pb:n:n:::a ron-1 Suresh Surana & Associates LLP Chartered Accountants Surem SUrana & Associates U.P 508-309, Technopohs Knowledge Park Mahakah Caves Road, Andhen (E) Mumt>a, - 400 093, India T • 91 (22) 6108 5555 ema,lsCi')ss-assoaates com wwv, 1s-assoaates.com UP Identity No AAB-7509 Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To The Board of Directors of Piramal Pharma Limited 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Piramal Pharma Limited ("the Company"), for the quarter ended 30 June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. This Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant Rules issued thereunder and other accounting principles genera [Showing first 8,000 characters — download PDF for full document]